ClinicalTrials.Veeva

Menu

Description and Prognostic Evaluation of Four Biological Parameters of Blast Cells in Adult Acute Lymphoblastic Leukemia

U

University Hospital, Angers

Status

Unknown

Conditions

Adult Acute Lymphoblastic Leukemia

Treatments

Procedure: S-Phase%
Procedure: DNA Index
Procedure: CD45 expression
Procedure: P16 metabolic way

Study type

Observational

Funder types

Other

Identifiers

NCT00188084
PHRC03-02
GOELAMS 271-003

Details and patient eligibility

About

Adult acute lymphoblastic leukemia treatment approaches relie on risk stratification, including cytogenetics. We want to study at diagnosis several blast cells parameters on frozen samples of GRAALL protocols enrolled patients:

  1. A CD45-DNA double staining analysed by flow cytometry will allow mesurement for each blastic clone of DNA ploidy, percentage of cells in S-phase, CD45 fluorescence index.
  2. The proteine P16 metabolic way, involved in cell cycle regulation, will be studied by Western Blot analysis.

The comparison between these parameters, and main haematological data, will be followed by a prognostic analysis, based on blast corticosensibility in vivo, chimiosensibility, complete remission, and survival.

Combination of the studied parameters will allow to appreciate a clonal diversity. This will help to predict, at diagnosis, high probability of resistance to treatment.

Sex

All

Ages

15 to 59 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • All GRAALL 2003 and 2005 enrolled patients with available frozen blast cells

Exclusion criteria

  • None

Trial contacts and locations

1

Loading...

Central trial contact

Agnès F CHASSEVENT, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems